var data={"title":"Aminophylline: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Aminophylline: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5615?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=aminophylline-drug-information\" class=\"drug drug_general\">see &quot;Aminophylline: Drug information&quot;</a> and <a href=\"topic.htm?path=aminophylline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Aminophylline: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133450\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Aminophylline Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056475\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiasthmatic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Bronchodilator</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Respiratory Stimulant</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Theophylline Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11431484\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> All dosages expressed as aminophylline; dose should be individualized based on serum concentrations. Due to longer half-life than older patients, the time to achieve steady-state serum concentration is prolonged in neonates (see theophylline half-life table); obtain serum theophylline concentration after 48 to 72 hours of therapy (usually 72 hours in neonates); repeat values should be obtained 3 days after each change in dosage or weekly if on a stabilized dosage. If renal function decreased, consider dose reduction and additional monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Apnea of prematurity:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 5.7 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;24 days: 1.27 mg/kg/dose every 12 hours to achieve a target concentration of 7.5 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &gt;24 days: 1.9 mg/kg/dose every 12 hours to achieve a target concentration of 7.5 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 5 to 8 mg/kg/dose; in a prospective randomized controlled trial of 61 neonates (birth weight: &lt;1,500 g), a loading dose of 8 mg/kg/dose achieved targeted theophylline serum concentrations in more patients compared to a loading dose of 6 mg/kg/dose (Hochwald 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: Initial: 2 to 6 mg/kg/day divided every 8 to 12 hours (Bhatt-Mehta 2003; Hochwald 2002); increased dosages may be indicated as liver metabolism increases; monitor serum concentrations to determine appropriate dosages</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Dose reduction and frequent monitoring of serum theophylline concentrations are required in neonates with decreased renal function; 50% of dose is excreted unchanged in the urine of neonates.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056470\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=aminophylline-drug-information\" class=\"drug drug_general\">see &quot;Aminophylline: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">All dosages expressed as <b>aminophylline</b>; use ideal body weight to calculate dose; adjust dose based on steady-state serum concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Obstructive airway disease, acute symptoms:</b> Infants, Children, and Adolescents: <b>Note:</b> Not recommended for the treatment of asthma exacerbations (GINA 2016; NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Loading dose:</i> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients <b>not currently receiving</b> aminophylline or theophylline: 5.7 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients <b>currently receiving</b> aminophylline or theophylline: A loading dose is not recommended without first obtaining a serum theophylline concentration in patients who have received aminophylline or theophylline within the past 24 hours. The loading dose should be calculated as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Dose = (C desired &ndash; C measured) (V<sub>d</sub>)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">C desired = desired serum theophylline concentration</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">C measured = measured serum theophylline concentration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance dose:</i> Continuous IV infusion: <b>Note:</b> Dosing presented is to achieve a target concentration of 10 mcg/mL. Lower initial doses may be required in patients with reduced theophylline clearance. Dosage should be adjusted according to serum concentration measurements during the first 12- to 24-hour period.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 4 to 6 weeks: 1.9 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 6 to 52 weeks: Dose (mg/kg/<b>hour</b>) = [(0.008 X age in weeks) + 0.21] divided by 0.79</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to &lt;9 years: 1.01 mg/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 9 to &lt;12 years: 0.89 mg/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents 12 to &lt;16 years (otherwise healthy, nonsmokers): 0.63 mg/kg/<b>hour</b>; maximum dose: 1,139 mg/<b>day</b> unless serum concentrations indicate need for larger dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents 12 to &lt;16 years (cigarette or marijuana smokers): 0.89 mg/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;16 years (otherwise healthy, nonsmokers): 0.51 mg/kg/<b>hour</b>; maximum dose: 1,139 mg/<b>day</b> unless serum concentrations indicate need for larger dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiac decompensation, cor pulmonale, hepatic dysfunction, sepsis with multiorgan failure, shock: Infants, Children, and Adolescents: Initial: 0.25 mg/kg/<b>hour</b>; maximum dose: 507 mg/<b>day</b> unless serum concentrations indicate need for larger dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Obstructive airway disease, acute symptoms: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Loading dose:</i> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients <b>not currently receiving </b>aminophylline or theophylline in the previous 24 hours: 5.7 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients <b>currently receiving</b> aminophylline or theophylline in the previous 24 hours: A loading dose is not recommended without first obtaining a serum theophylline concentration in patients who have received aminophylline or theophylline within the past 24 hours. The loading dose should be calculated as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dose = (desired serum theophylline concentration - measured serum theophylline concentration) (V<sub>d</sub>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance dose:</i> IV: <b>Note:</b> Dosing presented is to achieve a target theophylline concentration of 10 mcg/mL unless otherwise noted. Lower initial doses may be required in patients with reduced theophylline clearance. Dosage should be adjusted according to serum level measurements during the first 12- to 24-hour period.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &le;60 years (otherwise healthy, nonsmokers): 0.51 mg/kg/<b>hour</b>; maximum: 1,139 mg/<b>day</b> unless serum levels indicate need for larger dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &gt;60 years: 0.38 mg/kg/<b>hour</b>; maximum dose: 507 mg/<b>day</b> unless serum concentrations indicate need for larger dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiac decompensation, cor pulmonale, hepatic dysfunction, sepsis with multiorgan failure, shock: Initial: 0.25 mg/kg/<b>hour</b>; maximum dose: 507 mg/<b>day</b> unless serum concentrations indicate need for larger dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment based on serum theophylline concentrations:</b> Infants, Children, Adolescents, and Adults: Note: Recheck serum theophylline concentrations 12 hours (children) or 24 hours (adults) after IV dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;9.9 mcg/mL: If tolerated, but symptoms remain, increase dose by ~25%. Recheck serum theophylline concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">10 to 14.9 mcg/mL: Maintain dosage if tolerated and symptoms controlled. Recheck serum concentrations at 24-hour intervals. If symptoms not controlled, consider additional medications for management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">15 to 19.9 mcg/mL: Consider 10% dose reduction to improve safety margin even if dose is tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">20 to 24.9 mcg/mL: Decrease dose by ~25%. Recheck serum concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">25 to 30 mcg/mL: Stop infusion for 12 hours (children) or 24 hours (adults) and decrease subsequent doses by at least 25%. Recheck serum concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;30 mcg/mL: Stop dosing and treat overdose; if resumed, decrease subsequent doses by at least 50%. Recheck serum concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 1 to 3 months: There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; consider dose reduction and frequent monitoring of serum theophylline concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &gt;3 months, Children, Adolescents, and Adults: No adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Infants, Children, Adolescents, and Adults: Initial: 0.25 mg/kg/<b>hour</b>; maximum dose: 507 mg/<b>day</b> unless serum concentrations indicate need for larger dose. Use with caution and monitor serum theophylline concentrations frequently.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133426\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as dihydrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/mL (10 mL, 20 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133412\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056480\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: For IV administration only; IM use is not recommended; IM administration causes intense pain. Loading doses should be administered over 30 minutes; doses may be further diluted and infused over 20 to 30 minutes; maximum rate of infusion: 0.36 mg/kg/minute and should not exceed 25 mg/minute</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (See Management of Drug Extravasations for more details); remove needle/cannula; apply dry cold compresses (Hurst 2004); elevate extremity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471281\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 1 mg/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2572957\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) in original carton. Protect from light. Do not use if discolored or if crystals are present.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056479\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of symptoms and reversible airflow obstruction associated with asthma, COPD, or other chronic lung diseases [FDA approved in pediatric patients (age not specified) and adults]; has also been used for treatment of apnea of prematurity and to increase diaphragmatic contractility </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133500\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Aminophylline may be confused with amitriptyline, ampicillin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133498\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events observed at therapeutic serum levels:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache, insomnia, irritability, restlessness, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Allergic skin reaction, exfoliative dermatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Diuresis (transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tremor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133432\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to aminophylline, theophylline, ethylenediamine, or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Coronary artery disease where cardiac stimulation might prove harmful; peptic ulcer disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133416\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper catheter or needle position prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Theophylline toxicity: Severe and potentially fatal theophylline toxicity may occur if reduced theophylline clearance occurs. Theophylline clearance may be decreased in patients with acute pulmonary edema, heart failure, cor pulmonale, fever (&ge;102&deg;F for &ge;24 hours or lesser temperature elevations for longer periods), hepatic disease, acute hepatitis, cirrhosis, hypothyroidism, sepsis with multiorgan failure, shock, neonates (term and premature), infants &lt;3 months of age with decreased renal function, infants &lt;1 year, elderly &gt;60 years, and patients following cessation of smoking. Consider benefits versus risks and the need for more intensive monitoring in these patients; reduced infusion rate required. If a patient develops signs and symptoms of theophylline toxicity (eg, nausea or persistent, repetitive vomiting), a serum theophylline level should be measured immediately and subsequent doses withheld.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiac arrhythmias (excluding bradyarrhythmias); use may exacerbate arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cystic fibrosis: Use with caution in patients with cystic fibrosis; increased theophylline clearance may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment (eg, cirrhosis, acute hepatitis, cholestasis); risk of severe and potentially fatal theophylline toxicity is increased. Theophylline clearance is decreased &ge;50% in these patients. Dose reduction and frequent monitoring of serum theophylline concentrations are required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism; increased theophylline clearance may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peptic ulcer disease: Use with caution in patients with active peptic ulcer disease; use may exacerbate peptic ulcer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with seizure disorders; use may exacerbate seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use extreme caution in the elderly; these patients are at greater risk of serious theophylline toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Select dose with caution and with frequent monitoring of concentrations (especially &lt;1 year); rate of clearance is highly variable in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Do not increase dose in response to acute exacerbation of symptoms unless steady state serum theophylline concentration is &lt;10 mcg/mL. As the rate of theophylline clearance may be dose-dependent, an increase in dose based upon a subtherapeutic serum concentration measurement should be limited to ~25% increase of the previous infusion rate or daily dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133489\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133420\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12572&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acebrophylline: May enhance the stimulatory effect of Theophylline Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adalimumab: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adenosine: Theophylline Derivatives may diminish the therapeutic effect of Adenosine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May increase the serum concentration of Aminophylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antithyroid Agents: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzodiazepines: Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Theophylline Derivatives. Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Theophylline Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of CarBAMazepine. Management: Seek alternatives to this combination when possible.  If these agents are used together, monitor closely for decreased serum concentrations/therapeutic effects of both medications.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May decrease the metabolism of Theophylline Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inducers (Moderate): May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Theophylline Derivatives may enhance the adverse/toxic effect of Doxofylline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Febuxostat: May increase serum concentrations of the active metabolite(s) of Theophylline Derivatives. Specifically, concentrations of 1-methylxanthine, a metabolite of unknown clinical importance, may become elevated.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May decrease the metabolism of Theophylline Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Formoterol: Theophylline Derivatives may enhance the adverse/toxic effect of Formoterol. Theophylline Derivatives may enhance the hypokalemic effect of Formoterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of Fosphenytoin. Management: Seek alternatives when possible. If used together, monitor for decreased concentrations/effects of phenytoin or theophylline if the other agent is initiated/dose increased, or increased concentrations/effects if the other is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indacaterol: Theophylline Derivatives may enhance the adverse/toxic effect of Indacaterol. Theophylline Derivatives may enhance the hypokalemic effect of Indacaterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Interferons: May decrease the metabolism of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoproterenol: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Theophylline Derivatives may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May decrease the metabolism of Theophylline Derivatives.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin; Telithromycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mexiletine: May decrease the metabolism of Theophylline Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olodaterol: Theophylline Derivatives may enhance the adverse/toxic effect of Olodaterol. Theophylline Derivatives may enhance the hypokalemic effect of Olodaterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pancuronium: Theophylline Derivatives may enhance the adverse/toxic effect of Pancuronium. Theophylline Derivatives may diminish the neuromuscular-blocking effect of Pancuronium.  Management: Pancuronium dosage adjustment may be necessary to induce paralysis  in patients receiving concomitant theophylline derivatives. Monitor closely for adverse effects (e.g., cardiac effects) with concomitant use of these agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of Phenytoin. Management: Seek alternatives when possible. If used together, monitor for decreased concentrations/effects of phenytoin or theophylline if the other agent is initiated/dose increased, or increased concentrations/effects if the other is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May decrease the serum concentration of Theophylline Derivatives.<b> Exceptions: </b>Fosamprenavir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern.  Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents.<b> Exceptions: </b>Delafloxacin; Gemifloxacin; LevoFLOXacin (Systemic); Lomefloxacin; Moxifloxacin (Systemic); Nalidixic Acid; Pefloxacin; Sparfloxacin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regadenoson: Aminophylline may diminish the vasodilatory effect of Regadenoson. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Theophylline Derivatives may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfinpyrazone: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiabendazole: May decrease the metabolism of Theophylline Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopental: Aminophylline may diminish the therapeutic effect of Thiopental. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: May increase the metabolism of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticlopidine: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zafirlukast: Theophylline Derivatives may decrease the serum concentration of Zafirlukast. Zafirlukast may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zileuton: May increase the serum concentration of Aminophylline. Management: Reduce aminophylline dose by 50% upon initiation of zileuton therapy. If aminophylline is added to existing zileuton therapy, use a lower starting dose. Monitor for increased theophylline serum concentrations and effects.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133447\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethanol: Ethanol may decrease theophylline clearance. Management: Avoid or limit ethanol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Food: Theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef; a high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline. Management: Avoid extremes of dietary protein and carbohydrate intake.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133422\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133436\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Theophylline crosses the placenta. Refer to Theophylline monograph for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056474\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum theophylline concentrations, heart rate, respiratory rate, number and severity of apnea spells (when used for apnea of prematurity); arterial or capillary blood gases (if applicable); pulmonary function tests</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056478\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Therapeutic concentrations:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asthma: 5 to 15 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apnea of prematurity: 6 to 12 mcg/mL; goal concentration is reduced due to decreased protein binding and higher free fraction</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Guidelines for Drawing Theophylline Serum Concentrations</caption>\n      <col></col>\n      <col></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;text-align:center;\">Dosage Form</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;text-align:center;\">When to Obtain Sample<sup>A</sup></p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <sup>A</sup>The time to achieve steady-state serum concentration is prolonged in patients with longer half-lives (eg, infants and adults with cardiac or liver failure; see theophylline half-life table). In these patients, serum theophylline concentrations should be drawn after 48 to 72 hours of therapy; may need to obtain concentrations prior to steady-state to assess the patient's current progress or evaluate potential toxicity.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:center;\">IV bolus</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:center;\">30 min after end of 30-min infusion</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:center;\">Continuous IV infusion</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:center;\">12 to 24 h after initiation of infusion</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133415\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Theophylline has two distinct actions; smooth muscle relaxation (ie, bronchodilation) and suppression of the response of the airways to stimuli (ie, non-bronchodilator prophylactic effects). Bronchodilation is mediated by inhibition of two isoenzymes, phosphodiesterase (PDE III and, to a lesser extent, PDE IV) while non-bronchodilation effects are mediated through other molecular mechanisms. Theophylline increases the force of contraction of diaphragmatic muscles through enhancement of calcium uptake through adenosine-mediated channels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133431\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Theophylline:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Theophylline: ~0.45 L/kg based on ideal body weight; distributes poorly into body fat; V<sub>d</sub> may increase in premature neonates, hepatic cirrhosis, acidemia (uncorrected), elderly, and third trimester of pregnancy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Theophylline: ~40%, primarily to albumin; decreased in neonates (due to a greater percentage of fetal albumin), hepatic cirrhosis, acidemia (uncorrected), elderly, third trimester of pregnancy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Theophylline: Hepatic via demethylation (CYP 1A2) and hydroxylation (CYP 2E1 and 3A4); forms active metabolites (caffeine and 3-methylxanthine)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Theophylline: Highly variable and dependent upon age, hepatic function, cardiac function, lung disease, and smoking history</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature infants, postnatal age 3 to 15 days: 30 hours (range: 17 to 43 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature infants, postnatal age 25 to 57 days: 20 hours (range: 9.4 to 30.6 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Term infants, postnatal age 1 to 2 days: 25.7 hours (range: 25 to 26.5 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Term infants, postnatal age 3 to 30 weeks: 11 hours (range: 6 to 29 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 to 4 years: 3.4 hours (range: 1.2 to 5.6 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents 6 to 17 years: 3.7 hours (range: 1.5 to 5.9 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults &ge;18 years to &le;60 years (asthma, nonsmoking, otherwise healthy): 8.7 hours (range: 6.1 to 12.8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Elderly &gt;60 years (nonsmoking, healthy): 9.8 hours (range: 1.6 to 18 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance: Certain conditions may significantly alter theophylline clearance; severe and potentially fatal theophylline toxicity may occur if reduced theophylline clearance occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Decreased theophylline clearance: Neonates and infants; elderly &gt;60 years; acute pulmonary edema, cor pulmonale; fever (&ge;102&deg;F for &ge;24 hours or lesser temperature elevations for longer periods); heart failure; hepatic impairment (eg, cirrhosis, acute hepatitis, cholestasis); hypothyroidism; patients following cessation of smoking; sepsis with multiple organ failure; shock; third trimester of pregnancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Increased theophylline clearance: Hyperthyroidism; cystic fibrosis; smoking (ie, marijuana or tobacco).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Within 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Theophylline: Urine (~50% as unchanged drug [Neonates]; ~10% as unchanged drug [Infants &gt;3 months, Adolescents, and Adults])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15597805\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Clearance is very low in neonates and reaches max values by 1 year of age, remains relatively constant until about 9 years of age, and then slowly decreases by approximately 50% to adult values at about 16 years of age. Renal excretion of unchanged theophylline in neonates amounts to about 50% of the dose, compared to about 10% in children older than three months and in adults.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13796898\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Theophylline dose is 79% of aminophylline dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Each mg/kg of theophylline administered as a bolus will increase the serum theophylline concentration by an average of 2 mcg/mL.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133435\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aminophylline Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (10 mL): $0.82</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133438\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aminocont (FI);</li>\n      <li>Aminofilina (CO, CR, DO, EC, GT, HN, NI, PA, PL, SV);</li>\n      <li>Aminomal (CH, IT);</li>\n      <li>Aminophyllin (HR, NO);</li>\n      <li>Aminophylline Renaudin (FR);</li>\n      <li>Aminophyllinum (PL);</li>\n      <li>Aminophyllinum Prolongatum (PL);</li>\n      <li>Aminophyllinum Retard (HU, PL);</li>\n      <li>Aminoslow (LU);</li>\n      <li>Aminosol (PH);</li>\n      <li>Amlin (KR);</li>\n      <li>Asiphylline (TW);</li>\n      <li>Asmafilin (TR);</li>\n      <li>Asmafin (TR);</li>\n      <li>Asmapen (BR);</li>\n      <li>Asthcontin (KR);</li>\n      <li>Brolin (BD);</li>\n      <li>Cardiomin (CL);</li>\n      <li>Cardirenal (AR);</li>\n      <li>Cardophyllin (AU);</li>\n      <li>Carine (AU);</li>\n      <li>Clonofillin SR (HU);</li>\n      <li>Diaphyllin (HU, VN);</li>\n      <li>Escophyllin (CH);</li>\n      <li>Euphyllin (AT, BE, BH, CH, DE, LU, NL, SA);</li>\n      <li>Euphyllin Retard (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Filin (BD);</li>\n      <li>Filotempo (PT);</li>\n      <li>Lanrox (BD);</li>\n      <li>Minophyl (IN);</li>\n      <li>Minoton (BR);</li>\n      <li>Miofilin (RO);</li>\n      <li>Neophyllin (JP, QA, SG);</li>\n      <li>Pediatric Asthcontin for Children SR (KR);</li>\n      <li>Peterphyllin (ZA);</li>\n      <li>Phaminov (ID, PH);</li>\n      <li>Pharmafil (MX);</li>\n      <li>Phylin (BD);</li>\n      <li>Phyllocontin (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GB, GH, GM, GN, GY, ID, IE, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, PK, QA, SA, SC, SD, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Phyllocontin Continus (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Phyllotemp (CH, DE, GR);</li>\n      <li>Planphylline (FR);</li>\n      <li>Retafilin (HR);</li>\n      <li>Sofafyllin (BG);</li>\n      <li>Syntophyllin (CZ);</li>\n      <li>Tefamin (IT);</li>\n      <li>Teofyllamin Ipex (SE);</li>\n      <li>Xing You Shan (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aminophylline [prescribing information]. Lake Forest, IL: Hospira Inc; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronson JK, Hardman M, and Reynolds DJ, &quot;ABC of Monitoring Drug Therapy. Theophylline, &quot;<i>BMJ</i>, 1992, 305(6865):1355-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/1483087/pubmed\" target=\"_blank\" id=\"1483087\">1483087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt-Mehta V and Schumacher RE, &ldquo;Treatment of Apnea of Prematurity,&rdquo; <i>Paediatr Drugs</i>, 2003, 5(3):195-210.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/12608884/pubmed\" target=\"_blank\" id=\"12608884\">12608884</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2016. Available at: http://www.ginasthma.org. Accessed June 22, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hochwald C, Kennedy K, Chang J, et al, &quot;A Randomized, Controlled, Double-Blind Trial Comparing Two Loading Doses of Aminophylline,&quot; <i>J Perinatol</i>, 2002, 22(4):275-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/12032788/pubmed\" target=\"_blank\" id=\"12032788\">12032788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. <i>J Pharm Technol</i>. 1989;5(3):101-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminophylline-pediatric-drug-information/abstract-text/10318297 /pubmed\" target=\"_blank\" id=\"10318297 \">10318297 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo; Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12572 Version 163.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F133450\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1056475\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11431484\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1056470\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F133426\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F133412\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1056480\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14471281\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F2572957\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1056479\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F133500\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F133498\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F133432\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F133416\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F133489\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F133420\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F133447\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F133422\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F133436\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1056474\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1056478\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F133415\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F133431\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F15597805\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F13796898\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F133435\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F133438\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12572|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=aminophylline-drug-information\" class=\"drug drug_general\">Aminophylline: Drug information</a></li><li><a href=\"topic.htm?path=aminophylline-patient-drug-information\" class=\"drug drug_patient\">Aminophylline: Patient drug information</a></li></ul></div></div>","javascript":null}